DMARDS AND BRM’S
Today is the last in the series of discussions about the autoimmune disorders, particularly Rheumatoid Arthritis. Almost all of the compounds discussed previously, appear to work by attacking the symptoms of the problem such as the progression of joint erosion and or pain, swell etc. The DMARDS (Disease Modifying Anti-Rheumatic Drugs), also some known as BRM’s ( Biologic Response Modifiers) approach the problem by attempting to STOP or at least slow down the progression of the problem .The DMARDS and other biologics have been so successful that their use has spread, to the benefit of the patient.
The results being achieved differ by compound. However, the bottom line is that they appear to be working. Unfortunately like almost all newer meds that come to market there are downsides and drawbacks. Some require injection administration. Some have to be taken daily. Some are used monthly, and some have severe side effects such as nausea, vomiting pain etc. For these reasons, there is no “ONE SIZE FITS ALL”.Following is a list of some of these pharmaceuticals.. Please note that some are older, and have more detailed classifications, and those ending in “mab” appear to have similar mechanisms of actions. It is beyond the scope of this piece to be more specific and the reader is referred as always to his/her own medical provider.
Chemical name Retail name
hydroxychloroquine Plaquennil
leftunomide Arava
methotrexate Trexall
sulfasalazine Azulidine
minocycline Minocine
abatocept Orencia
rituximab Rituxan
tocioizumab Actemra
anakinra Kineret
adalimmab Humira
etanercept Embrel
infliximab Remicade
certolizumab pegol Cimzia
gulimumab Simponi
This concludes the coverage on the Auto Immune maladies. Next week starts a sharing of notes from the Journal of the American Medical Society. (JAMA.)